Pyridines

Akebia Presents Results from its PRO2TECT Global Phase 3 Program of Vadadustat for the Treatment of Anemia due to Chronic Kidney Disease in Adult Patients Not on Dialysis During Late-Breaking Session at American Society of Nephrology Kidney Week 2020 Reim

Retrieved on: 
Friday, October 23, 2020
Chemical compounds, Acetic acids, Medical specialties, Anatomy, Kidney diseases, Pyridines, Vadadustat, Chronic kidney disease, Dialysis, Anemia, Roxadustat, Molidustat

"The PRO2TECT results show that orally administered vadadustat achieved both primary and secondary efficacy endpoints in patients not on dialysis with anemia associated with CKD.

Key Points: 
  • "The PRO2TECT results show that orally administered vadadustat achieved both primary and secondary efficacy endpoints in patients not on dialysis with anemia associated with CKD.
  • Akebia's vadadustat development program also includes INNO2VATE, the global Phase 3 program for the treatment of anemia due to CKD in adult patients on dialysis.
  • Results from this program were presented at ASN Kidney Weekin an oral presentation on October 22, 2020.
  • In Japan, vadadustat is approved as a treatment for anemia due to CKD in both dialysis-dependent and non-dialysis dependent adult patients.

Nanoform initiates GMP campaign for first-in-human trial of nanoformed drug by year end - ahead of schedule

Retrieved on: 
Tuesday, October 20, 2020
Health, Nonsteroidal anti-inflammatory drugs, Pharmaceutical sciences, Medicinal chemistry, Pyridines, Clinical pharmacology, Hepatotoxins, Piroxicam, Oxicam, Pharmaceutical industry, Pharmaceutical formulation, Bioavailability

The clinical trial is a progression of Nanoform's first GMP campaign, which the company has now initiated, and will be made in partnership with Quotient Sciences ("Quotient"), a leading provider of drug development and manufacturing solutions.

Key Points: 
  • The clinical trial is a progression of Nanoform's first GMP campaign, which the company has now initiated, and will be made in partnership with Quotient Sciences ("Quotient"), a leading provider of drug development and manufacturing solutions.
  • In the clinical trial, Nanoform will investigate the behavior of an oral immediate release (IR) nanoformedformulation of piroxicam, an anti-inflammatory drug.
  • Nanoform will manufacture the nanoformed piroxicam active pharmaceutical ingredient (API), which will then be transferred to Quotient's facilities in Nottingham, UK.
  • Quotient will support the project by developing a standard drug formulation for the nanoformed piroxicam API and administering it to healthy volunteers.

Eyenovia to Present Clinical Study Updates at the American Academy of Optometry Annual Meeting

Retrieved on: 
Monday, October 5, 2020
Health, Other Health, General Health, Clinical trials, Pharmaceutical, Optical, Biotechnology, RTT, Drugs, Muscarinic antagonists, Psychoactive drugs, Chemical compounds, Phenols, Pyridines, Tropicamide, Atropine, Phenylephrine, Optometry, Near-sightedness

Siddarth Rathi and April Jasper will present the latest analyses and updates from the companys clinical studies at the American Academy of Optometry Academy 2020 At Home Con .

Key Points: 
  • Siddarth Rathi and April Jasper will present the latest analyses and updates from the companys clinical studies at the American Academy of Optometry Academy 2020 At Home Con .
  • Clinical results will cover Pupil Dilation Speed with MAP Fixed Combination (FC) Tropicamide 1% Phenylephrine 2.5% (TR-PH)-Ophthalmic Solution.
  • Eyenovia, Inc. (NASDAQ: EYEN) is a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose array print (MAP) therapeutics.
  • MicroPine (atropine ophthalmic solution) is being evaluated in the CHAPERONE Phase 3 clinical study for reduction in pediatric myopia progression.

Europe Pruritus Market and Competitive Landscape Report 2020 - ResearchAndMarkets.com

Retrieved on: 
Monday, September 21, 2020
Health, Pharmaceutical, Pyridines, Market share, Market structure, Marketing strategy, Niacin, Microeconomics, Market economics)

The "Europe Pruritus Market and Competitive Landscape - 2020" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Europe Pruritus Market and Competitive Landscape - 2020" report has been added to ResearchAndMarkets.com's offering.
  • Europe Pruritus Market and Competitive Landscape - 2020, provides comprehensive insights into the Pruritus pipeline, epidemiology, market valuations, drug sales, market forecast, drug forecasts, and market shares.
  • This research analyzes and forecasts the Pruritus market size and drug sales.
  • This research covers the following:
    Pruritus treatment options, Pruritus late stage clinical trials pipeline, Pruritus prevalence by countries, Pruritus market size and forecast by countries, key market events and trends, drug sales and forecast by countries, and market shares by countries.

LYNPARZA® (olaparib) Reduced the Risk of Death by 31% in BRCA1/2 or ATM-mutated Metastatic Castration-Resistant Prostate Cancer in Phase III Profound Trial

Retrieved on: 
Sunday, September 20, 2020
Radiology, Biotechnology, Pharmaceutical, Oncology, General Health, Health, FDA, Clinical trials, Organic compounds, Drugs, Clinical medicine, Prostate cancer, RTT, Androstanes, Pyridines, Antineoplastic drugs, Abiraterone acetate, Chemotherapy, MCRPC, Olaparib, Metastatic Castration-Resistant Prostate Cancer (mCRPC), Homologous Recombination Repair (HRR) Gene Mutations, PROfound, LYNPARZA, the AstraZeneca and Merck strategic oncology collaboration, AstraZeneca in oncology, AstraZeneca

AstraZeneca and Merck are exploring additional trials in metastatic prostate cancer including the ongoing Phase III PROpel trial testing LYNPARZA as a 1st-line medicine for patients with mCRPC in combination with abiraterone versus abiraterone alone.

Key Points: 
  • AstraZeneca and Merck are exploring additional trials in metastatic prostate cancer including the ongoing Phase III PROpel trial testing LYNPARZA as a 1st-line medicine for patients with mCRPC in combination with abiraterone versus abiraterone alone.
  • Do not start LYNPARZA until patients have recovered from hematological toxicity caused by previous chemotherapy (Grade 1).
  • Embryo-Fetal Toxicity: Based on its mechanism of action and findings in animals, LYNPARZA can cause fetal harm.
  • LYNPARZA is the foundation of AstraZenecas industry-leading portfolio of potential new medicines targeting DDR mechanisms in cancer cells.

AVEO Oncology Announces European Urology Publication of Final Overall Survival Data from Phase 3 TIVO-3 Study of Tivozanib in Renal Cell Carcinoma

Retrieved on: 
Tuesday, September 15, 2020
Biotechnology, Health, Pharmaceutical, Clinical trials, Oncology, Chemical compounds, Organic compounds, Cancer treatments, Ureas, Pyridines, Angiogenesis inhibitors, Chloroarenes, Sorafenib, Tivozanib, Hepatocellular carcinoma, Renal cell carcinoma, Evofosfamide, Tivozanib (FOTIVDA, AVEO Pharmaceuticals, Inc.

AVEO Oncology (Nasdaq: AVEO) today announced that final overall survival (OS) results from its Phase 3 TIVO-3 study were published in the journal European Urology.

Key Points: 
  • AVEO Oncology (Nasdaq: AVEO) today announced that final overall survival (OS) results from its Phase 3 TIVO-3 study were published in the journal European Urology.
  • The article, titled Final Overall Survival Results from a Phase 3 Study to Compare Tivozanib to Sorafenib as Third- or Fourth-line Therapy in Subjects with Metastatic Renal Cell Carcinoma, is available online first via this link .
  • We expect that Tivozanibs TIVO-3 data has the potential to guide important treatment decisions in this setting and ultimately improve outcomes and patient experience.
  • AVEO is working to develop and potentially commercialize tivozanib in North America as a treatment for renal cell carcinoma and hepatocellular carcinoma.

Knight Therapeutics Announces Filling of Supplement to a New Drug Submission for NERLYNX® (neratinib) to Treat HER2-Positive Metastatic Breast Cancer

Retrieved on: 
Thursday, September 3, 2020
Organic compounds, Chemical compounds, Aromatic compounds, Cancer treatments, Chloroarenes, Neratinib, Pyridines, Quinolines, Puma Biotechnology, HER2/neu, Breast cancer

MONTREAL, Sept. 03, 2020 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX:GUD) ("Knight"), a pan-American (ex-US) specialty pharmaceutical company, announced filing of the Supplement to a New Drug Submission (SNDS) of NERLYNX for HER2-Positive Metastatic Breast Cancer in Canada.

Key Points: 
  • MONTREAL, Sept. 03, 2020 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX:GUD) ("Knight"), a pan-American (ex-US) specialty pharmaceutical company, announced filing of the Supplement to a New Drug Submission (SNDS) of NERLYNX for HER2-Positive Metastatic Breast Cancer in Canada.
  • Knight and Puma Biotechnology, Inc. (NASDAQ: PBYI) signed a licensing agreement in January 2019 granting Knight the exclusive right to commercialize NERLYNX (neratinib) in Canada.
  • Under the terms of the License Agreement, Knight will be responsible for all commercial activities and future regulatory submissions for NERLYNX in Canada.
  • HER2-positive breast cancer is often more aggressive than other types of breast cancer, increasing the risk of disease progression and death2.

Akebia Therapeutics Announces First Commercial Launch of VAFSEO™ (vadadustat tablets), a New Oral Treatment for Anemia Due to Chronic Kidney Disease, in Japan

Retrieved on: 
Wednesday, August 26, 2020
Chemical compounds, Medical specialties, Acetic acids, RTT, Anatomy, Kidney diseases, Organ failure, Pyridines, Vadadustat, Chronic kidney disease, Anemia, Dialysis

Anemia is common in patients with CKD, and its prevalence increases as CKD progresses.

Key Points: 
  • Anemia is common in patients with CKD, and its prevalence increases as CKD progresses.
  • Vadadustat is in global Phase 3 development for the treatment of anemia due to CKD and is not yet approved outside of Japan.
  • In Japan, vadadustat is approved as a treatment for anemia due to CKD in both dialysis-dependent and non-dialysis dependent adult patients.
  • Akebia Therapeutics , Inc. is a fully integrated biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease.

Global Pyridine Derivatives Market: Growth, Trends and Forecast (2020-2025) - ResearchAndMarkets.com

Retrieved on: 
Wednesday, August 26, 2020
Chemicals, Plastics, Manufacturing, Chemical compounds, Aromatic compounds, Organic compounds, Pyridines, Picoline, Pyridine, Forecast period, Beta, Forecast

The "Global Pyridine Derivatives Market: Growth, Trends and Forecast (2020-2025)" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Pyridine Derivatives Market: Growth, Trends and Forecast (2020-2025)" report has been added to ResearchAndMarkets.com's offering.
  • The global market for pyridine derivatives is expected to grow at a CAGR of over 5% during the forecast period.
  • Beta type of Picoline is expected to dominate the pyridine derivatives market accross the globe during the forecast timeline.
  • All the aforementioned factors are expected to drive the pyridine derivatives market during the forecast period.

Alpha 4 Beta 2 Neuronal Nicotinic Receptor (NNR) Agonist Pipeline Insight, 2020 - ResearchAndMarkets.com

Retrieved on: 
Thursday, August 13, 2020
Health, Pharmaceutical, Chemical compounds, Nicotinic agonists, Branches of biology, Organic compounds, Ion channels, Stimulants, Pyridines, Nicotinic acetylcholine receptors, RJR-2429, Nicotinic antagonist

The "Alpha 4 Beta 2 Neuronal Nicotinic Receptor (NNR) Agonist - Pipeline Insight, 2020" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Alpha 4 Beta 2 Neuronal Nicotinic Receptor (NNR) Agonist - Pipeline Insight, 2020" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • A detailed picture of the Alpha 4 Beta 2 Neuronal Nicotinic Receptor (NNR) Agonist pipeline landscape is provided, which includes the topic overview and Alpha 4 Beta 2 Neuronal Nicotinic Receptor (NNR) Agonist mechanism of action.
  • The assessment part of the report embraces, in-depth Alpha 4 Beta 2 Neuronal Nicotinic Receptor (NNR) Agonist commercial assessment and clinical assessment of the pipeline products under development.
  • Different therapeutic candidates in early-stage, mid-stage and late stage of development for Alpha 4 Beta 2 Neuronal Nicotinic Receptor (NNR) Agonist.